Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Optimal vitamin D spurs serotonin: 1,25-dihydroxyvitamin D represses serotonin reuptake transport (SERT) and degradation (MAO-A) gene expression in cultured rat serotonergic neuronal cell lines.

Sabir MS, Haussler MR, Mallick S, Kaneko I, Lucas DA, Haussler CA, Whitfield GK, Jurutka PW.

Genes Nutr. 2018 Jul 11;13:19. doi: 10.1186/s12263-018-0605-7. eCollection 2018.

2.

Graviola (Annona muricata) Exerts Anti-Proliferative, Anti-Clonogenic and Pro-Apoptotic Effects in Human Non-Melanoma Skin Cancer UW-BCC1 and A431 Cells In Vitro: Involvement of Hedgehog Signaling.

Chamcheu JC, Rady I, Chamcheu RN, Siddique AB, Bloch MB, Banang Mbeumi S, Babatunde AS, Uddin MB, Noubissi FK, Jurutka PW, Liu YY, Spiegelman VS, Whitfield GK, El Sayed KA.

Int J Mol Sci. 2018 Jun 16;19(6). pii: E1791. doi: 10.3390/ijms19061791.

3.

A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics.

Hanish BJ, Hackney Price JF, Kaneko I, Ma N, van der Vaart A, Wagner CE, Jurutka PW, Marshall PA.

Steroids. 2018 Jul;135:36-49. doi: 10.1016/j.steroids.2018.04.009. Epub 2018 Apr 26.

PMID:
29704526
4.

Bioactive Dietary VDR Ligands Regulate Genes Encoding Biomarkers of Skin Repair That Are Associated with Risk for Psoriasis.

Karrys A, Rady I, Chamcheu RN, Sabir MS, Mallick S, Chamcheu JC, Jurutka PW, Haussler MR, Whitfield GK.

Nutrients. 2018 Feb 4;10(2). pii: E174. doi: 10.3390/nu10020174.

5.

Gene Expression Profiling and Assessment of Vitamin D and Serotonin Pathway Variations in Patients With Irritable Bowel Syndrome.

Dussik CM, Hockley M, Grozić A, Kaneko I, Zhang L, Sabir MS, Park J, Wang J, Nickerson CA, Yale SH, Rall CJ, Foxx-Orenstein AE, Borror CM, Sandrin TR, Jurutka PW.

J Neurogastroenterol Motil. 2018 Jan 30;24(1):96-106. doi: 10.5056/jnm17021.

6.

SIRT1 enzymatically potentiates 1,25-dihydroxyvitamin D3 signaling via vitamin D receptor deacetylation.

Sabir MS, Khan Z, Hu C, Galligan MA, Dussik CM, Mallick S, Stone AD, Batie SF, Jacobs ET, Whitfield GK, Haussler MR, Heck MC, Jurutka PW.

J Steroid Biochem Mol Biol. 2017 Sep;172:117-129. doi: 10.1016/j.jsbmb.2017.06.010. Epub 2017 Jun 19.

7.

Total and Free Circulating Vitamin D and Vitamin D-Binding Protein in Relation to Colorectal Cancer Risk in a Prospective Study of African Americans.

Andersen SW, Shu XO, Cai Q, Khankari NK, Steinwandel MD, Jurutka PW, Blot WJ, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1242-1247. doi: 10.1158/1055-9965.EPI-17-0133. Epub 2017 May 8.

8.

Greater Adherence to Cancer Prevention Guidelines Is Associated with Higher Circulating Concentrations of Vitamin D Metabolites in a Cross-Sectional Analysis of Pooled Participants from 2 Chemoprevention Trials.

Kohler LN, Hibler EA, Harris RB, Oren E, Roe DJ, Jurutka PW, Jacobs ET.

J Nutr. 2017 Mar;147(3):421-429. doi: 10.3945/jn.116.243352. Epub 2017 Jan 25.

9.

EDITORIAL (Thematic Issue : Rexinoids).

Wagner CE, Marshall PA, Jurutka PW.

Curr Top Med Chem. 2017;17(6):629-630. No abstract available.

PMID:
28117026
10.

Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).

Heck MC, Wagner CE, Shahani PH, MacNeill M, Grozic A, Darwaiz T, Shimabuku M, Deans DG, Robinson NM, Salama SH, Ziller JW, Ma N, van der Vaart A, Marshall PA, Jurutka PW.

J Med Chem. 2016 Oct 13;59(19):8924-8940. Epub 2016 Sep 19.

PMID:
27592633
11.

Retinoid X Receptor Selective Agonists and their Synthetic Methods.

Wagner CE, Jurutka PW, Marshall PA, Heck MC.

Curr Top Med Chem. 2017;17(6):742-767. Review.

PMID:
27320333
12.

Association between Circulating Vitamin D Metabolites and Fecal Bile Acid Concentrations.

Jacobs ET, Haussler MR, Alberts DS, Kohler LN, Lance P, Martínez ME, Roe DJ, Jurutka PW.

Cancer Prev Res (Phila). 2016 Jul;9(7):589-97. doi: 10.1158/1940-6207.CAPR-16-0033. Epub 2016 May 2.

13.

Vitamin D and Colorectal, Breast, and Prostate Cancers: A Review of the Epidemiological Evidence.

Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW.

J Cancer. 2016 Jan 5;7(3):232-40. doi: 10.7150/jca.13403. eCollection 2016. Review.

14.

1,25-Dihydroxyvitamin D and Klotho: A Tale of Two Renal Hormones Coming of Age.

Haussler MR, Whitfield GK, Haussler CA, Sabir MS, Khan Z, Sandoval R, Jurutka PW.

Vitam Horm. 2016;100:165-230. doi: 10.1016/bs.vh.2015.11.005. Epub 2016 Jan 13.

PMID:
26827953
15.

Physical activity, sedentary behavior, and vitamin D metabolites.

Hibler EA, Sardo Molmenti CL, Dai Q, Kohler LN, Warren Anderson S, Jurutka PW, Jacobs ET.

Bone. 2016 Feb;83:248-255. doi: 10.1016/j.bone.2015.11.016. Epub 2015 Nov 24.

16.

CYP24A1 and CYP27B1 Polymorphisms, Concentrations of Vitamin D Metabolites, and Odds of Colorectal Adenoma Recurrence.

Hibler EA, Klimentidis YC, Jurutka PW, Kohler LN, Lance P, Roe DJ, Thompson PA, Jacobs ET.

Nutr Cancer. 2015;67(7):1131-41. doi: 10.1080/01635581.2015.1068818. Epub 2015 Aug 4.

17.

FGF23 gene regulation by 1,25-dihydroxyvitamin D: opposing effects in adipocytes and osteocytes.

Kaneko I, Saini RK, Griffin KP, Whitfield GK, Haussler MR, Jurutka PW.

J Endocrinol. 2015 Sep;226(3):155-66. doi: 10.1530/JOE-15-0225. Epub 2015 Jul 6.

18.

Distinct functional modes of SUMOylation for retinoid X receptor alpha.

Lee WP, Jena S, Rodriguez EP, O'Donovan SP, Wagner C, Jurutka PW, Thompson PD.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):195-200. doi: 10.1016/j.bbrc.2015.06.115. Epub 2015 Jun 23.

PMID:
26116533
19.

1,25-Dihydroxyvitamin D regulates expression of the tryptophan hydroxylase 2 and leptin genes: implication for behavioral influences of vitamin D.

Kaneko I, Sabir MS, Dussik CM, Whitfield GK, Karrys A, Hsieh JC, Haussler MR, Meyer MB, Pike JW, Jurutka PW.

FASEB J. 2015 Sep;29(9):4023-35. doi: 10.1096/fj.14-269811. Epub 2015 Jun 12.

PMID:
26071405
20.

Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles.

Marshall PA, Jurutka PW, Wagner CE, van der Vaart A, Kaneko I, Chavez PI, Ma N, Bhogal JS, Shahani P, Swierski JC, MacNeill M.

Pharmacol Res Perspect. 2015 Mar;3(2):e00122. doi: 10.1002/prp2.122. Epub 2015 Mar 16.

Supplemental Content

Loading ...
Support Center